Top Markets
#1 Akedo Akedo +58.73%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +47.62%
#4 Velvet Velvet +38.36%
#5 Black Phoenix Black Phoenix +33.94%
#6 Cross Cross +27.05%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.76%
#8 QANplatform QANplatform +14.60%
#9 Perle Perle +14.17%
#10 Bitway Bitway +13.96%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals Ltd.

BVXV
Rank in Stocks #38547
BiondVax Pharmaceuticals Ltd. is an Israeli-based biopharmaceutical company... BiondVax Pharmaceuticals Ltd. is an Israeli-based biopharmaceutical company currently in its development stage. Its core mission involves the research, production, and market introduction of therapeutic products designed for the prevention and treatment of a range of infectious and other medical conditions. The company has established strategic licensing and collaboration agreements with prominent scientific institutions, notably the Max Planck Society and the University Medical Center Göttingen. These partnerships are geared towards the advancement and commercialization of nanosized antibodies (NanoAbs), including a specific candidate for COVID-19, and extending this technology to address various other disease indications. Founded in 2003, BiondVax maintains its corporate headquarters in Jerusalem, Israel.
Share Price
$0.8
Last synced: 2023-10-03
Market Cap
$922.40K
Change (1 day)
-5.88%
Change (1 year)
0.00%
Country
IL
Trade BiondVax Pharmaceuticals Ltd. (BVXV)

Category

Healthcare
Revenue for BiondVax Pharmaceuticals Ltd. (BVXV)
Revenue in Aug 2026 TTM: 0
According to BiondVax Pharmaceuticals Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for BiondVax Pharmaceuticals Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE